Cytori Therapeutics (CYTX)

We continue to be very positive on Cytori Therapeutics (CYTX - Analyst Report) and believe the company's Celution System, a better mousetrap for quickly and efficiently harvesting adult stem cells, will see sales ramp significantly over the next few years.

Sales of the system have been tracking with our expectations. Ultimately, the clinical data will determine the pace at which the ramp continues. So far, the clinical data has been exciting, and with several investigator-sponsored programs ongoing. Additional data expected over the next few years will have an immediate impact on the financial results.

Today's price represents a very attractive entry point in our view. We are maintaining our Outperform rating and $8 target.

Cytori Therapeutics (CYTX) : FULL ANALYST REPORT

Email	Print	Share	RSS	Rate Pos	Rate Neg	Comment

Loading Stories...

Related Content

RELATED ARTICLES BULL OF THE DAY ARCHIVE

Zacks Equity Research: Report For CYTD
N/A	12/14/09
Zacks Blog: Zacks Bull and Bear of the Day Highlights: Cytori Therapeutics, Red Robin Gourmet Burgers Inc., Ford, Eaton and TRW Automotive
(CYTX, RRGB, F, ETN, TRW)	10/19/09
Zacks Blog: Zacks Analyst Blog Highlights: Cytori Therapeutics, Luminex Corp., Bank of NY Mellon, First Advantage Corporation and First American Corporation
(CYTX, LMNX, BK, FADV, FAF)	06/30/09
Zacks Blog: Cytori's IP and Cash Position Solid
(CYTX)	06/29/09
Zacks Blog: Cytori’s Celution Starting to Ramp
(CYTX)	05/11/09

 Posting Comment...

There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]

Comments (Limit 1000 Characters - Used: 0)

Please provide your comments here... Display Name: Email Address:  

 Loading Comments...

Be the first to comment on this article!